Remote detection of arthritis flare in patients with rheumatoid arthritis who are tapering their arthritis drug treatment Musculoskeletal Diseases
Conditions
Interventions
Observational study: Patients tapering disease-modifying anti-rheumatic drug (DMARD) therapy as part of routine standard care will be invited to wear a wrist accelerometer device for up to 6 months. R
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of RA made by a consultant rheumatologist 2. Disease activity score in 28 joints with C-reactive protein (DAS28-CRP) <2.4 at the point of enrolment to the study 3. Currently (or expected within the next 28 days) tapering of a DMARD (conventional synthetic, targeted synthetic, or biologic) 4. Able to walk at least four metres independently without walking aids 5. Participants willing to commit to complete remote RA-FQ questionnaires and continuously wear monitoring devices
Exclusion criteria
Exclusion criteria: 1. Current or recent (within the past 12 months) use of rituximab 2. Current or recent (within the past 12 months) use of oral, intramuscular, intravenous or intra-articular glucocorticoids for arthritis treatment (note that topical glucocorticoids and short courses of systemic glucocorticoids for other indications such as lung or skin conditions are permitted) 3. Escalation of DMARD therapy (i.e. initiation of new DMARD or increase in DMARD dose) within the past 12 months (note that dose reductions are permitted) 4. Unable to read or communicate in English 5. Inability to provide informed consent 6. Age less than 18 years 7. Current diagnosis of a movement disorder 8. Physical disability that would prevent wearing a wrist device (e.g. bilateral upper limb amputation or congenital deformity) 9. Current pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rheumatoid arthritis flare, defined as a disease activity score in 28 joints with C-reactive protein (DAS28-CRP) = 2.4, measured using data collected by the wrist accelerometer device at one time point | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactKenneth Baker
Outcome results
None listed